Today: 7 February 2026
Subscribe
Browse Category

ASX:TLX News 11 December 2025 - 27 January 2026

Telix Pharmaceuticals share price jumps 8% on ASX:TLX as JPMorgan crosses 5% — what to watch next

Telix Pharmaceuticals share price jumps 8% on ASX:TLX as JPMorgan crosses 5% — what to watch next

Sydney, Jan 28, 2026, 07:02 AEDT — Premarket Telix Pharmaceuticals Ltd shares grabbed attention ahead of the Australian open, closing Tuesday up 8.31% at A$11.86. The jump came after the company filed a fresh “substantial holder” notice with the exchange. (Intelligent Investor) Telix’s rebound catches attention, given it’s been one of healthcare’s worst performers in the last year, plunging roughly 57% over 12 months, according to market data. The company focuses on therapeutic and diagnostic radiopharmaceuticals — radioactive drugs for imaging and treatment — with Illuccix as its flagship imaging product. (MarketScreener) Telix is also a popular target for short
27 January 2026
······
Telix stock price slides 8% as investors digest FY25 revenue update and China Illuccix filing

Telix stock price slides 8% as investors digest FY25 revenue update and China Illuccix filing

Sydney, Jan 21, 2026, 17:33 AEDT — Markets have closed for the day. Telix Pharmaceuticals shares dropped 7.7% on Wednesday, settling at A$10.61. The decline came as investors digested a new quarterly update alongside a regulatory move in China related to its prostate cancer imaging business. (Google) This move is significant as Telix’s valuation remains heavily dependent on growth in its commercial scans, even as the market watches closely for progress in its broader pipeline, which has faced regulatory hurdles in the United States. Late Tuesday, Telix reported unaudited full-year group revenue of roughly US$804 million, matching its upgraded forecast.
21 January 2026
·····
Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals Limited (ASX:TLX, Nasdaq:TLX) entered the spotlight again on December 17, 2025, as TLX stock extended its December sell-off amid a fast-moving mix of clinical-trial updates, regulatory overhang, and investor litigation headlines. Telix Pharmaceuticals+2Investing.com+2 On the ASX, Telix shares closed at A$11.73, down 6.61% on the session, with a wide intraday range from A$11.535 to A$12.730 and volume of roughly 6.36 million shares—a notably volatile day by recent standards. Investing.com+1 In the U.S., Telix’s Nasdaq-listed shares/ADS were also under pressure, with U.S. market coverage noting a gap-down move and a roughly 6%–7% decline in early trading action on Dec.
17 December 2025
······
Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

December 11, 2025 Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) is ending 2025 in a paradoxical position: commercially successful, rich in late‑stage oncology assets, but trading near its 12‑month lows amid SEC scrutiny, an FDA setback and a growing stack of class‑action lawsuits. At the same time, new clinical milestones and a fresh collaboration with Varian are reinforcing the long‑term radiopharmaceutical growth story. This overview pulls together today’s news, the latest clinical and legal developments, and current analyst forecasts as of 11 December 2025. Telix share price today: depressed after a volatile year By midday in New York on 11
11 December 2025
······

Stock Market Today

Verizon stock price snaps 7-day run as consumer chief exit sharpens focus on turnaround

Verizon stock price snaps 7-day run as consumer chief exit sharpens focus on turnaround

7 February 2026
Verizon shares fell 1.7% to $46.31 Friday, ending a seven-session rally and closing about 2.7% below Thursday’s one-year high. The dip follows news that consumer chief Sowmyanarayan Sampath will step down, with Alfonso Villanueva named interim head. Verizon has climbed 16% since January 29 amid strong subscriber growth and a $25 billion buyback plan.
Cisco stock jumps 3% near $85 as UBS sticks with Buy ahead of Feb. 11 earnings

Cisco stock jumps 3% near $85 as UBS sticks with Buy ahead of Feb. 11 earnings

7 February 2026
Cisco shares rose 3% to $84.82 Friday, nearing $85 ahead of fiscal Q2 results due Feb. 11. UBS maintained a Buy rating and $90 target, citing strong product order growth and data-center demand. Investors are watching AI-related spending and U.S. economic data that could affect rates. Peers Fortinet, CrowdStrike, and Palo Alto Networks also gained.
Coherent stock whiplash: COHR jumps after earnings drop — what to watch next week

Coherent stock whiplash: COHR jumps after earnings drop — what to watch next week

7 February 2026
Coherent Corp shares jumped 8.8% to $227.68 Friday, rebounding after a two-day slide following its quarterly results. The company reported December-quarter revenue of $1.69 billion and non-GAAP earnings of $1.29 a share, with datacenter and communications driving 72% of sales. Barclays, Stifel, and JPMorgan raised price targets to $235–$245. FMR LLC disclosed a 15% stake as of Dec. 31.
Go toTop